Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

Nikki Parker, Mary Jo Turk, Elaine Westrick et al. · Analytical Biochemistry · 2005 · 1.2K citations

Veterinary Medicine, Biochemistry, Oncology +7

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.

Steven Weitman, Richard H. Lark, Leslie R. Coney et al. · PubMed · 1992 · 1K citations

Medicine, Cancer Biology, Oncology +8

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

John F. Ross, P. K. Chaudhuri, Manohar Ratnam · Cancer · 1994 · 889 citations

Medicine, Molecular Biology, Oncology +14

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger et al. · Journal of Clinical Oncology · 2013 · 233 citations

Medicine, Oncology, Pharmacology +16

Synthesis and Biological Evaluation of EC20:  A New Folate-Derived, ^99mTc-Based Radiopharmaceutical

Christopher P. Leamon, Matthew Parker, Iontcho R. Vlahov et al. · Bioconjugate Chemistry · 2002 · 207 citations

Medicine, Oncology, Pharmacology +16